Please login to the form below

Not currently logged in
Email:
Password:

Hikma makes USD 163.6m cash offer for Arab Pharmaceutical

UK-based Hikma Pharmaceuticals has made a conditional offer to acquire Jordanian pharmaceutical company Arab Pharmaceutical Manufacturing (APM) for approximately USD 163.6m in cash.

UK-based Hikma Pharmaceuticals has made a conditional offer to acquire Jordanian pharmaceutical company Arab Pharmaceutical Manufacturing (APM) for approximately USD 163.6m in cash.

The generics company already has a significant presence in the Middle East and North Africa (MENA) region, the US and Europe.

The APM offer is conditional upon the successful completion of due diligence and the approval of APM shareholders.

Merrill Lynch International is acting as financial advisor to Hikma for the transaction.

Hikma is currently trading at GBP 445.20 on the LSE, up GBP 0.020 or 0.04 per cent.

For H1 FY07, Hikma racked up USD 224.9m in revenue, compared with USD 154.9m in H1 FY06, a rise of 45.2 per cent. Operating profit was 51.8m, compared with USD 42.2m. Diluted EPS was USD 20.2m, compared with USD 17.2m, an increase of 17.4 per cent.

In H1 FY07, Hikma began production at its new cephalosporin plant in Portugal for the MENA region and Europe. The company also entered the injectable oncology market through the acquisitions of Ribosepharm and Thymoorgan in Germany and acquired 10 new oncology products. The company also entered the Egyptian market when it signed an agreement to acquire Alkan Pharma in August 2007.

30th September 2008

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....
Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...